15th European AIDS Conference (EACS), October 21-24, 2015, Barcelona

Conference Reports for NATAP


15th European AIDS Conference (EACS) October 21-24, 2015 Barcelona

	Better Virologic Control After Switch From Boosted ATV/TDF/FTC to E/C/F/TAF - Mark Mascolini - (11/06/15) Atazanavir plus Cobicistat versus Atazanavir plus Ritonavir, Both in Combination with Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial - (11/05/15) Real-World Assessment of Renal and Bone Safety Among Patients Exposed to Tenofovir Disoproxil Fumarate-Containing Single Tablet Regimens - (11/05/15) Real-World Cardiovascular Outcomes of Atazanavir - (11/05/15) Bioequivalence of a Fixed-Dose Combination of Rilpivirine/Emtricitabine/Tenofovir Alafenamide to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Rilpivirine - (11/05/15) Where is the greatest impact of uncontrolled HIV infection on clinical disease progression? - (11/05/15) ChemSex: Data on Recreational Drug Use and Sexual Behaviour in Men Who Have Sex with Men (MSM) from a Busy Sexual Health Clinic in London, UK - (11/03/15) Differing cART Responses in Naive Women and Those With Short-Term cART in Pregnancy - Mark Mascolini (11/03/15) HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen - (11/03/15) The Effect of Food on the Pharmacokinetics of Unboosted and Boosted Tenofovir Alafenamide - (11/03/15) Patient Reported Outcomes Over 48 Weeks in a Randomized, Open-Label Trial of Patients With HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) - (11/03/15) Elvitegravir concentrations in seminal plasma in HIV-1 infected patients - (11/02/15) Long lasting viral suppression and immune reconstitution (CD4) of great magnitude reduce the risk of cervical dysplasia in HIV-positive women - (11/02/15) Integrated Analysis of Emergent Drug Resistance Through 48 Weeks from Clinical Studies of HIV-1 Treatment-Naive Subjects Receiving E/C/F/TAF - (11/02/15) Evaluation of Tenofovir Alafenamide Pharmacokinetics: No Influence of Demographic or HIV Disease Factors - (11/02/15) Lung Function Decline in HIV: Effects of Immediate vs. Deferred ART Treatment on Lung Function Decline in a Multi-site, International, Randomized Controlled Trial - START - (11/02/15) Ongoing contribution of AIDS deaths in the HAART era - (10/30/15) PERSISTENT HIV LOW-LEVEL VIREMIA AND CARDIOVASCULAR RISK - (10/30/15) The Effect of Food on the Rilpivirine/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen - (10/30/15) Trends in incidences and risk factors for hepatocellular carcinoma & other liver events in HIV/HCV co-infected individuals from 2001 to 2014: a multi-cohort study - (10/30/15) No decline in hepatitis C incidence among HIV-positive MSM; an update from the CASCADE Collaboration - (10/30/15) Recurrent Lymphoma Infrequent With HIV, But Prognosis Remains Poor - Written by Mark Mascolini (10/30/15) Most AIDS Deaths Involve Women, Blacks, and Younger People in UK Cohort - Written by Mark Mascolini (10/30/15) Nonclassic OIs and AIDS Cancers Occurring at Higher CD4 Counts in Swiss Cohort - Written by Mark Mascolini (10/30/15) Pre-ART Load, Time to Suppression, and Regimen Predict Rebound - Written by Mark Mascolini (10/30/15) Pharmacokinetics of ATV/r or DRV/r in + 2 NRTIs among HIV-1-naive Patients with Severe Immunosuppression - IMEA 040-DATA sub-study - Written by Mark Mascolini (10/30/15) Nonclassic OIs and AIDS Cancers Occurring at Higher CD4 Counts in Swiss Cohort...... "AIDS Defining Opportunistic Diseases in the Swiss HIV Cohort Study: A Comprehensive Review 1988-2013" - Written by Mark Mascolini (10/30/15) Persistent Low Viremia Not Tied to Heart Disease, AIDS, or Death in Large Cohort - Written by Mark Mascolini (10/28/15) Dual therapy with Lopinavir/ Ritonavir (LPV/r) and Lamivudine (3TC) is non-inferior to standard triple drug therapy in Naïve HIV-1 infected subjects : 48-week results of the GARDEL Study. (10/28/15) Switching From Boosted Atazanavir Plus Emtricitabine /Tenofovir Disoproxil Fumarate to a Tenofovir Alafenamide-Based Single-Tablet Regimen: Week-48 Data in Virologically Suppressed Adults (10/28/15) Gap in ART Response Between Women and MSM Not Narrowing in London.....women and MSW have worse virologic responses to ART than MSM (10/28/15) Is the gender difference in viral load response to ART narrowing over time? Women Non-Viral Response Double vs MSM (10/28/15) Low-level viremia (LLV) ranging from 50 to 500 copies/mL is associated to an increased risk of AIDS events in the Icona Foundation Cohort (10/28/15) Week 48 results of the randomised, multicentre Maraviroc Switch study (MARCH) (10/28/15) Switch to maraviroc (MVC) + darunavir/ritonavir (DRV/r) in virologically suppressed patients with R5-tropic virus is associated with an excess of virological failures: 48 weeks results of the GUSTA study (10/28/15) Measuring Safety and Satisfaction of ABC/DTG/3TC (Triumeq) in a Switch Trial: Secondary Endpoints from the STRIVING Study (10/28/15) EuroSIDA Analysis Suggests Much Lower PSA Cutoff for HIV-Positive Men - Written by Mark Mascolini (10/28/15) Birth Defect Rate Low and Similar With Darunavir and Other Antiretroviral Regimens - Written by Mark Mascolini (10/27/15) Viral Load of 51 to 500 Boosts Risk of AIDS But Not Serious Non-AIDS Illness - Written by Mark Mascolini (10/27/15) EuroSIDA Analysis Suggests Much Lower PSA Cutoff for HIV-Positive Men - Written by Mark Mascolini (10/27/15) No Neuropsych Test Difference Between Early and Delayed ART in START (10/27/15) A Randomized, Double-Blind Comparison of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, for Initial HIV-1 Treatment: Week 96 Results (10/27/15) No Difference between the Effects of Immediate versus Deferred ART on Neuropsychological Test Performance in HIV-Positive Adults with CD4+ Cell Counts > 500 cells/μL (10/27/15) Dolutegravir Monotherapy in HIV-infected Patients with Sustained Viral Suppression: A 24-week Pilot Study (10/27/15) TAF in Women/WAVES Global Women's Study - The Efficacy and Safety of Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve Women With HIV-1 Infection: Week 48 Analysis of the Phase 3, Randomized, Double-blind Study (10/27/15) TURQUOISE-I STUDY: USE OF OMBITASVIR/PARITAPREVIR/RITONAVIR + DASABUVIR + RIBAVIRIN IN PATIENTS WITH HCV/HIV-1 CO-INFECTION ON STABLE DARUNAVIR-CONTAINING ANTIRETROVIRAL THERAPY (10/27/15) Sofosbuvir plus ledipasvir for 8 weeks in HCV-mono- and HIV-HCV-coinfected patients - Results from the German hepatitis C cohort (GECCO) (10/27/15) Near-100% SVR12 With 8 Weeks of Sofosbuvir/Ledipasvir in German HIV+/HIV- Cohort - Written by Mark Mascolini (10/27/15) Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients?..... "SVR -reduced incidence of liver-related death and improved overall survival" (10/27/15) Dolutegravir monotherapy in patients with suppressed HIV viremia. (10/26/15) HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Safety Analysis (10/26/15) Changes in cognitive function over 96 weeks after initiating darunavir/ritonavir with either raltegravir or tenofovir-emtricitabine; NEAT 001 / ANRS 143 randomised controlled study (10/26/15) Improved Safety and Efficacy of TAF vs TDF Single-Tablet Regimen in HIV-1 Treatment-Naïve Women Through Week 48 (10/26/15) Simplification to Atazanavir/Ritonavir + Lamivudine versus Maintaining Atazanavir/Ritonavir + 2NRTIs in Virologically Suppressed HIV-infected Patients: 48-weeks Data of the ATLAS-M Trial (10/26/15) Week 48 results of the randomised, multicentre Maraviroc Switch study (MARCH) (10/26/15) Pre-cART pro-Inflammatory Milieu, Microbial Translocation (MT) and risk of disease progression in HIV-Infected Patients, Starting Their First cART: data form the Icona Cohort Foundation (10/26/15) Measuring Safety and Satisfaction of ABC/DTG/3TC in a Switch Trial: Secondary Endpoints from the STRIVING Study (10/26/15) Week 48 results of the randomised, multicentre Maraviroc Switch study (MARCH) (10/26/15) HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Safety Analysis (10/26/15) Frailty Predicts All-cause Mortality, Hospital Admission and Falls in HIV-infected and -uninfected Middle-aged Individuals (10/23/15) Second-generation HIV-1 Maturation Inhibitor BMS-955176: Overall Antiviral Activity and Safety Results from the Phase IIa Proof-of-Concept Study (AI468002) (10/23/15) Second Generation HIV-1 Maturation Inhibitor (MI) BMS-955176: Antiviral Activity Toward Non-B Subtype HIV-1 Viruses (10/23/15) Immediate ART in START Linked to Bigger Bone Loss Over 3 Years - written Mark Mascolini (10/23/15) HIV Independently Boosts Odds of Hypertension in Older HIV+/HIV- Cohort - Lipodystrophy/heart disease - written Mark Mascolini (10/23/15) Pilot Study Finds Good 24-Week Response to First-Line Dolutegravir/3TC - written Mark Mascolini (10/23/15) Dolutegravir-Lamivudine as Initial Therapy in HIV-infected, ARV Naïve Patients: First Results of the PADDLE Study - (10/23/15) Dolutegravir-Based Regimens Viral Load Decay at week 4 Could predict Sustained Viral Suppression - (10/23/15) HIV Independently Boosts Odds of Hypertension in Older HIV+/HIV- Cohort - (10/23/15) Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV - (10/23/15)